The company designed the proprietary device to provide both short- and long-term protection for those nerve injuries. It features a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel facilitates enhanced nerve gliding to aid in minimizing soft tissue attachments. The base layer remodels into a long-term protective tissue layer.
According to a news release, nerve injuries for this protection category include a wide range of injuries and defects. Axogen lists nerve compression, crush and complex traumatic injuries. The company aims to optimize outcomes with targeted solutions to adequately address the nerve and the surrounding environment.
Dr. Peter J. Evans of the Cleveland Clinic (Florida Region) said Axoguard HA+ could potentially “greatly impact patients.” Its impact could especially come for those where the injury falls in proximity to high-mobility joints, he said. Evans also noted that the increased gliding feature and optimized handling enable surgeons to address the challenges of nerve injuries early and in most critical healing phases.
“Axoguard HA+ is an important extension of our nerve protection platform,” said Karen Zaderej, Axogen chair, CEO, and president. “The release of Axoguard HA+ expands opportunities for surgeons to treat a wider range of nerve protection challenges.”
